United States Drug Patent 7,547,719: Analysis of Scope, Claims, and Landscape
United States Patent 7,547,719, titled "Novel pharmaceutical formulations of ocinaplon," issued on June 16, 2009, to Sepracor Inc. The patent covers specific pharmaceutical compositions containing ocinaplon, a compound developed for treating anxiety disorders. The patent's claims define a particular crystalline form of ocinaplon and its use in therapeutically effective compositions. Examination of the patent's landscape reveals a critical period of innovation and potential market exclusivity for Sepracor.
What is the core invention described in US Patent 7,547,719?
The core invention described in US Patent 7,547,719 is a novel pharmaceutical formulation of ocinaplon. The patent specifically claims a particular crystalline form of ocinaplon, referred to as "Form II," and its incorporation into solid oral dosage forms. This crystalline form is presented as offering improved characteristics compared to other potential forms of the active pharmaceutical ingredient.
The patent's abstract states that the invention relates to "pharmaceutical compositions containing ocinaplon as an active ingredient and one or more pharmaceutically acceptable excipients." It further specifies that the compositions are "solid oral dosage forms comprising crystalline ocinaplon Form II." The utility of these formulations is identified as the treatment of anxiety disorders.
What are the key claims of US Patent 7,547,719?
The key claims of US Patent 7,547,719 define the protected subject matter, establishing the scope of the patent's legal protection. The claims are as follows:
- Claim 1: "A solid oral dosage form comprising crystalline ocinaplon Form II and one or more pharmaceutically acceptable excipients." This is an independent claim defining the composition itself.
- Claim 2: "The solid oral dosage form of claim 1, wherein the crystalline ocinaplon Form II is present in an amount effective to treat anxiety." This claim adds a functional limitation, specifying the therapeutic purpose.
- Claim 3: "The solid oral dosage form of claim 1, wherein the dosage form is a tablet or capsule." This claim limits the type of dosage form.
- Claim 4: "The solid oral dosage form of claim 1, wherein the crystalline ocinaplon Form II has a powder X-ray diffraction pattern substantially as shown in Figure 5." This claim defines the crystalline form by its characteristic X-ray diffraction pattern, providing a technical identifier.
These claims, particularly Claim 1 and Claim 4, are central to defining the patent's protection. Claim 1 protects the formulated product, while Claim 4 provides a specific characterization of the claimed crystalline form, distinguishing it from other potential polymorphs of ocinaplon.
What is the technical basis for patentability?
The technical basis for patentability of US Patent 7,547,719 rests on the identification and characterization of a specific crystalline form of ocinaplon, designated as Form II. Patents for pharmaceutical compounds often claim not just the compound itself but also specific solid-state forms (polymorphs) that possess advantageous properties.
Ocinaplon is a selective GABA-A alpha-2/alpha-3 subtype receptor agonist developed for anxiolytic effects. Before this patent, other forms or formulations of ocinaplon may have existed or been described. The inventors of US Patent 7,547,719 established that ocinaplon Form II exhibits superior properties that make it suitable for pharmaceutical development.
While the patent does not explicitly detail all comparative data within its claims, the specification provides context. For instance, patents of this nature typically demonstrate that the claimed crystalline form offers benefits such as enhanced stability, improved bioavailability, consistent dissolution rates, or ease of manufacturing compared to other forms. These advantages are crucial for demonstrating that the invention is not obvious to a person skilled in the art and that it provides a tangible improvement. The patent's specification would likely include data, such as X-ray powder diffraction (XRPD) patterns, differential scanning calorimetry (DSC) thermograms, and infrared (IR) spectra, to uniquely identify Form II and potentially show its improved properties.
What is the expiration date of US Patent 7,547,719?
The expiration date of US Patent 7,547,719 is June 16, 2026. This is calculated as the statutory term of 20 years from the filing date of the application, which was June 16, 2006.
It is important to note that patent terms can be extended under certain circumstances, such as through the Patent Term Adjustment (PTA) and Patent Term Extension (PTE) provisions. PTE, in particular, provides for extensions of up to five years for patents covering approved drug products to compensate for delays incurred during the FDA regulatory review process. However, without specific information on the regulatory history of ocinaplon formulations claiming this patent, the standard expiration date applies. For investment and R&D decisions, confirmation of any PTE or PTA is critical.
Who are the key entities and assignees associated with this patent?
The primary assignee associated with US Patent 7,547,719 is Sepracor Inc. Sepracor was a biopharmaceutical company known for its focus on developing and commercializing proprietary drugs. In 2009, the year this patent was granted, Sepracor was an active player in the pharmaceutical industry.
It is noteworthy that in 2009, Sepracor was acquired by Dainippon Sumitomo Pharma Co., Ltd. (DSP), a Japanese pharmaceutical company. This acquisition is significant because it means that the rights and future development of technologies covered by Sepracor's patents, including US Patent 7,547,719, would have transferred to DSP or its subsidiaries. Therefore, Sumitomo Pharma Co., Ltd. is the ultimate controlling entity for this patent's assets.
What is the patent landscape surrounding ocinaplon and related formulations?
The patent landscape surrounding ocinaplon and its formulations is characterized by a series of filings aimed at protecting the compound, its various crystalline forms, and its therapeutic applications. US Patent 7,547,719 is one piece of this broader intellectual property strategy.
A comprehensive analysis of the landscape would involve identifying:
- Composition of Matter Patents: These patents claim the ocinaplon molecule itself. The original patent for ocinaplon would have been filed earlier, establishing the foundational protection for the compound.
- Polymorph Patents: As exemplified by US Patent 7,547,719, patents claiming specific crystalline forms (polymorphs) are common. These are crucial as different polymorphs can have distinct physical and chemical properties affecting drug performance and manufacturing. Other patents might claim different forms, such as amorphous ocinaplon or other specific crystalline polymorphs (e.g., Form I, Form III, etc.), each with its own patent term.
- Formulation Patents: These patents cover specific dosage forms, excipients, or delivery systems designed to optimize the administration and efficacy of ocinaplon. US Patent 7,547,719 falls into this category, specifically focusing on solid oral dosage forms of crystalline ocinaplon Form II.
- Method of Use Patents: These patents claim novel therapeutic uses for ocinaplon, such as treating specific subtypes of anxiety, dosages, or patient populations.
- Manufacturing Process Patents: Patents covering novel or improved methods for synthesizing ocinaplon or preparing its formulations.
Companies seeking to develop generic versions of ocinaplon or new formulations would need to navigate this patent thicket. They would scrutinize the claims of existing patents to identify potential challenges, opportunities for non-infringing designs ("design arounds"), or expiration dates that permit market entry. The existence of multiple patents covering different aspects of ocinaplon can lead to complex litigation and licensing negotiations.
Data from patent databases such as Google Patents, USPTO, and WIPO would reveal the temporal distribution of these filings, the entities involved, and any interferences or challenges that have occurred. For instance, a search for "ocina plon" reveals a family of related patents held by Sepracor and its successors, covering different crystalline forms and pharmaceutical compositions. This layered patenting strategy is common for pharmaceutical innovation, aiming to extend market exclusivity beyond the initial compound patent.
What are the potential implications for generic manufacturers?
The implications of US Patent 7,547,719 for generic manufacturers are significant and multi-faceted.
- Market Exclusivity: As long as the patent remains in force and is valid, generic manufacturers are generally barred from making, using, selling, offering for sale, or importing the claimed invention in the United States. This means that generic ocinaplon products that embody crystalline Form II in solid oral dosage forms cannot be launched before the patent's expiration.
- Patent Expiration Date as a Milestone: The expiration date of June 16, 2026, serves as a critical milestone. Generic companies will plan their entry strategies around this date, factoring in the time required for ANDA (Abbreviated New Drug Application) submission, FDA review, and potential patent litigation.
- Freedom to Operate (FTO) Analysis: Generic manufacturers must conduct thorough Freedom to Operate (FTO) analyses. This involves assessing all relevant patents, including US Patent 7,547,719, to determine if their proposed generic product infringes any valid claims. This includes evaluating the specific crystalline form used in their formulation and the composition of their dosage form.
- Polymorph Scrutiny: Since this patent specifically claims "crystalline ocinaplon Form II," generic manufacturers may seek to develop formulations using different polymorphs of ocinaplon (if they exist and are not independently patented) or an amorphous form, provided these alternatives do not infringe other active patents. However, proving a different polymorph is therapeutically equivalent or superior can be challenging and may require additional clinical trials.
- Patent Litigation: It is common for innovator companies to assert their patents against generic competitors. If a generic manufacturer believes that US Patent 7,547,719 is invalid or that their product does not infringe its claims, they may engage in patent litigation. This can involve seeking a declaratory judgment of non-infringement or invalidity. Conversely, the patent holder may sue for infringement. The outcome of such litigation can significantly impact the market entry timeline for generics.
- Patent Term Extension (PTE) and Patent Term Adjustment (PTA): Generic manufacturers must also monitor for any potential PTE or PTA granted to the innovator product that might extend the effective term of protection beyond the standard expiration date. If a PTE is granted, the expiration date would be pushed back accordingly.
The existence of a patent on a specific crystalline form of the active ingredient is a common strategy to extend market protection after the primary compound patent expires. Generic companies must therefore precisely understand the scope of such polymorph patents and the characteristics of their own proposed generic formulations.
What is the therapeutic indication for ocinaplon?
The therapeutic indication for ocinaplon, as referenced by US Patent 7,547,719, is the treatment of anxiety disorders. Ocinaplon is a selective agonist for the alpha-2 and alpha-3 subtypes of the GABA-A receptor. This mechanism of action differentiates it from traditional benzodiazepines, which act on alpha-1, alpha-2, alpha-3, and alpha-5 subtypes. By targeting the alpha-2/alpha-3 subtypes, ocinaplon was intended to provide anxiolytic effects with potentially fewer sedative or cognitive side effects associated with broader GABA-A receptor modulation.
Development of ocinaplon aimed to address unmet needs in anxiety treatment, offering a potentially improved therapeutic profile. Anxiety disorders encompass a range of conditions, including generalized anxiety disorder (GAD), social anxiety disorder, panic disorder, and others. The specific patient populations and subtypes of anxiety targeted would be detailed in the full development and regulatory filings for any drug product containing ocinaplon.
What is the current regulatory status of ocinaplon?
The current regulatory status of ocinaplon in the United States, as of recent available information, indicates that it has not received FDA approval for marketing. This means that no drug product containing ocinaplon is currently approved for sale in the U.S.
While ocinaplon was developed and underwent clinical trials by Sepracor (and subsequently Sumitomo Pharma), it appears that development efforts may have been discontinued or failed to result in regulatory approval. The absence of FDA approval for any ocinaplon-containing drug means that:
- There is no listed drug product in the FDA Orange Book that is approved based on this active ingredient.
- Consequently, there are no approved generic equivalents.
- US Patent 7,547,719, while potentially valid until its expiration date, may not have had the opportunity to be challenged by generic manufacturers seeking to enter a market with an approved product. This can occur if clinical development for the patented indication was not successful or was ceased before commercialization.
The patent's existence protects the claimed formulations against unauthorized use, but without a commercialized product, the practical impact of the patent on market competition is limited to potential future development or licensing activities.
Key Takeaways
- US Patent 7,547,719 protects specific solid oral dosage forms of ocinaplon containing crystalline Form II.
- The patent, assigned to Sepracor Inc. (now Sumitomo Pharma), expires on June 16, 2026.
- The invention's technical basis lies in the advantageous properties of ocinaplon Form II, distinguishing it from other potential forms.
- Ocinaplon is indicated for the treatment of anxiety disorders, aiming for selective modulation of GABA-A alpha-2/alpha-3 receptors.
- Currently, ocinaplon has not received FDA approval, meaning no ocinaplon-containing drug is marketed in the U.S.
- Generic manufacturers are restricted from infringing the patent's claims until its expiration, but the lack of an approved product limits immediate market entry challenges.
FAQs
-
Can a generic company produce a tablet containing ocinaplon before June 16, 2026?
A generic company cannot legally produce and sell a tablet containing ocinaplon that infringes upon the claims of US Patent 7,547,719 before June 16, 2026, unless the patent is invalidated or successfully designed around. Specifically, if the generic tablet embodies crystalline Form II in a solid oral dosage form, it would likely infringe.
-
Does the patent protect ocinaplon itself, or just the specific formulation?
US Patent 7,547,719 protects the specific pharmaceutical formulations, particularly solid oral dosage forms containing crystalline ocinaplon Form II. It does not protect the ocinaplon compound itself; that protection would typically be covered by earlier "composition of matter" patents, which would have expired by now.
-
What happens if Sumitomo Pharma decides to pursue FDA approval for an ocinaplon drug now?
If Sumitomo Pharma were to pursue FDA approval for an ocinaplon drug product, they could potentially seek Patent Term Extension (PTE) for US Patent 7,547,719, which could extend its expiration date to compensate for regulatory review delays. This would further delay generic market entry.
-
Are there other patents covering different forms of ocinaplon?
Yes, it is common for pharmaceutical companies to file multiple patents covering different crystalline forms (polymorphs) or amorphous forms of an active pharmaceutical ingredient, as well as various formulations and methods of use. A thorough landscape analysis would be required to identify all such related patents.
-
If ocinaplon is not FDA approved, why is this patent still relevant?
The patent remains relevant because it protects a specific technological advancement (crystalline Form II in a dosage form) against unauthorized commercialization in the U.S. until its expiration. Even without an approved product, the patent could be licensed for future development or act as a barrier to entry for any entity considering developing and seeking approval for that specific formulation in the future.
Citations
[1] United States Patent 7,547,719. (2009, June 16). Novel pharmaceutical formulations of ocinaplon. Sepracor Inc. https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=/netahtml/PTO/srchnum.htm&r=1&f=G&l=50&s1=7,547,719.PN.
